Determinants of the recommended dietary allowance (RDA) for vitamin C include the relationship between vitamin C dose and steady-state plasma concentration, bioavailability, urinary excretion, cell concentration, and potential adverse effects. Because current data are inadequate, an in-hospital depletion-repletion study was conducted. Seven healthy volunteers were hospitalized for 4-6 months and consumed a diet containing <5 mg of vitamin C daily. Steady-state plasma and tissue concentrations were determined at seven daily doses of vitamin C from 30 to 2500 mg. Vitamin C steady-state plasma concentrations as a function of dose displayed sigmoid kinetics. The steep portion of the curve occurred between the 30-and 100-mg daily dose, the current RDA of 60 mg daily was on the lower third of the curve, the first dose beyond the sigmoid portion of the curve was 200 mg daily, and complete plasma saturation occurred at 1000 mg daily. Neutrophils, monocytes, and lymphocytes saturated at 100 mg daily and contained concentrations at least 14-fold higher than plasma. Bioavailability was complete for 200 mg of vitamin C as a single dose. No vitamin C was excreted in urine of six of seven volunteers until the 100-mg dose. At single doses of 500 mg and higher, bioavailability declined and the absorbed amount was excreted. Oxalate and urate excretion were elevated at 1000 mg of vitamin C daily compared to lower doses. Based on these data and Institute of Medicine criteria, the current RDA of 60 mg daily should be increased to 200 mg daily, which can be obtained from fruits and vegetables. Safe doses of vitamin C are less than 1000 mg daily, and vitamin C daily doses above 400 mg have no evident value.
ABSTRACT
Determinants of the recommended dietary allowance (RDA) for vitamin C include the relationship between vitamin C dose and steady-state plasma concentration, bioavailability, urinary excretion, cell concentration, and potential adverse effects. Because current data are inadequate, an in-hospital depletion-repletion study was conducted. Seven healthy volunteers were hospitalized for 4-6 months and consumed a diet containing <5 mg of vitamin C daily. Steady-state plasma and tissue concentrations were determined at seven daily doses of vitamin C from 30 to 2500 mg. Vitamin C steady-state plasma concentrations as a function of dose displayed sigmoid kinetics. The steep portion of the curve occurred between the 30-and 100-mg daily dose, the current RDA of 60 mg daily was on the lower third of the curve, the first dose beyond the sigmoid portion of the curve was 200 mg daily, and complete plasma saturation occurred at 1000 mg daily. Neutrophils, monocytes, and lymphocytes saturated at 100 mg daily and contained concentrations at least 14-fold higher than plasma. Bioavailability was complete for 200 mg of vitamin C as a single dose. No vitamin C was excreted in urine of six of seven volunteers until the 100-mg dose. At single doses of 500 mg and higher, bioavailability declined and the absorbed amount was excreted. Oxalate and urate excretion were elevated at 1000 mg of vitamin C daily compared to lower doses. Based on these data and Institute of Medicine criteria, the current RDA of 60 mg daily should be increased to 200 mg daily, which can be obtained from fruits and vegetables. Safe doses of vitamin C are less than 1000 mg daily, and vitamin C daily doses above 400 mg have no evident value.
The recommended dietary allowance (RDA) for vitamin C is 60 mg daily, based on threshold urinary excretion of the vitamin and on preventing the vitamin C deficiency disease scurvy with a margin of safety (1, 2) .. Ingestion of 60 mg daily was proposed to prevent scurvy for [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] days if vitamin C intake ceased (1) (2) (3) (4) (5) (6) (7) . Threshold urinary excretion of vitamin C was reported at the 60-mg daily dose (3, 4, 7, 8) . Tissue stores were thought to be near saturation at 60 mg, and increased excretion would occur at higher doses (1) (2) (3) (4) (5) (6) (7) (8) .
To establish an RDA for a vitamin, it is necessary to determine vitamin concentrations in plasma and tissues in relation to vitamin dose for a wide range of doses, true bioavailability or vitamin absorption at each dose, vitamin urinary excretion at each dose, and potential toxicity (1, 2, 9) . In theory these data could be obtained from nutrition depletion-repletion studies in combination with pharmacokinetic
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principles. For vitamin C, however, the information is unavailable, incomplete, or flawed (3) (4) (5) (6) (7) (8) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) Assays and Data Calculation. Samples for vitamin C were analyzed by HPLC with coulometric electrochemical detection as described (27, 28) . Every sample was divided into three aliquots and analyzed separately. Blood and urine samples were stored on ice in a dark refrigerator until prepared for assay as described (27, 28) Table 1 ). Dose indicates the amount of vitamin C administered daily. (Fig. 1C) (Fig. 2 ). Vitamin C in purified monocytes and lymphocytes also reached maximum concentration at 100 mg daily (Fig. 2) . (Fig. 1C) . At higher vitamin C doses, bioavailability declined: <50% of the 1250-mg dose was absorbed. Plateau plasma vitamin C was close to maximum at 200 mg daily (Fig. 1C ), but at higher doses bioavailability did not Fig. 3 for details. decrease proportionally ( Table 2 ). The explanation could be vitamin C urinary excretion (32) . Urine was collected throughout bioavailability sampling, during both oral and intravenous administration of vitamin C. Less than 0.4 mg of vitamin C appeared in urine of all volunteers after single doses of 15 and 30 mg (Fig. 4) . After single doses of 50 mg, six of seven subjects had <0.4 mg of vitamin C in urine. At the plateau for the 60-mg daily dose (immediately prior to the 50-mg bioavailability sampling), vitamin C excretion was <0.4 mg in 24-h urine collections from several volunteers (data not shown). From 100 mg of vitamin C as a single dose administered orally or i.v., urine excretion was -25 mg. At 500-and 1250-mg single doses, urine excretion was greater for i.v. than oral vitamin C, consistent with decreased bioavailability at these doses (Table  2 ). Fractional excretion was determined for vitamin C administered intravenously (Fig. 4 Inset B) . The 500-and 1250-mg doses were entirely excreted in urine. Fig. 1B ). Since samples were not drawn daily, the volunteer remained on the dose for >3 weeks after plateau was achieved (Fig. 1B) . The different shape of the curves in Fig. 1A Twenty-four-hour urine uric acid and oxalate excretion as a function of daily vitamin C dose. Urine uric acid (e) (lefty axis) and urine oxalate (0) (right y axis) were measured in 24-h urine samples at plateau of each vitamin C dose. Values in brackets are P values for excretion compared to excretion at the 1000-mg vitamin C dose. Numbers in parentheses are the number of subjects whose urine was analyzed. Samples were not available for vitamin C daily doses of 2500 mg. Uric acid was analyzed by a coupled measurement of hydrogen peroxide formed by uricase (38) when urine vitamin C was -5 mg/dl (vitamin C doses of 30, 60, and 100 mg). In this assay vitamin C at 1 mg/dl produces a decrease of 1 mg/dl in measured uric acid. For higher vitamin C doses, urinary uric acid was analyzed by a modified uricase method (39) . Urine oxalate was analyzed by a coupled assay using oxalate oxidase and horseradish peroxidase; samples were treated with activated charcoal to avoid vitamin C interference (40) urate and oxalate excretion (Fig. 5) . Excretion of both was significantly higher at plateau of the 1000-mg daily dose compared to lower doses. There were no differences when other doses were compared to each other.
Laboratory tests were unchanged from baseline during depletion and repletion at all doses, except for ferritin. Ferritin decreased for each patient presumably due to study-related blood loss. Bleeding times were normal.
High doses of vitamin C had no adverse clinical impact. For example, these doses did not cause diarrhea or abdominal cramps (11) . At the nadir of depletion, mild but consistent feelings of fatigue and/or irritability were elicited from six of seven volunteers. These symptoms resolved in three volunteers within 1 week after the 30-mg daily dose was begun, and in the other three volunteers within 1 week after the 60-mg daily dose was begun. At the lowest and highest vitamin C doses, there were no differences in psychometric testing for each volunteer (data not shown). At (35) (36) (37) . If high doses were administered longer, it is unclear whether the elevations would remain and whether renal calculi would result. When patients ingested .1000 mg of vitamin C daily, unexpected calculi were not reported (51, (54) (55) (56) . Based on our new data, recent urinary excretion findings (36, 37) applied to women because it is possible that they achieve higher plasma concentrations at lower doses compared to men (14, 15) . The data here are also relevant to subjects over a wide age range, although it is possible that the elderly will require more ascorbate than younger subjects (19, 20, 22) .
Bioavailability of the 200-mg dose was complete when calculated by using the linear trapezoidal method (30, 31 
